Ipratropiumbromide 40 Cyclocaps Teva (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic acetylcholine receptors (M1, M2, M3) on airway smooth muscle and submucosal glands. By preventing acetylcholine binding, it reduces intracellular calcium, leading to relaxation of bronchial smooth muscle and inhibition of glandular secretions, which produces bronchodilation and decreases nasal mucus production.

The prescribed dose of Ipratropiumbromide 40 µg Cyclocaps is determined by the treating physician based on the individual’s condition, severity, and response to therapy. Patients should follow the dosing instructions provided on the prescription label and by their healthcare professional.

The pregnancy safety category for ipratropium bromide is unknown. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; mothers should discuss potential risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipratropium bromide is an anticholinergic bronchodilator, differing from β2‑agonists such as albuterol, which stimulate β2‑adrenergic receptors. It provides a complementary mechanism of action, often used as add‑on therapy to improve lung function when β2‑agonists alone are insufficient, and has a lower risk of tachycardia.

Store the cyclocaps at ambient temperature, below 25 °C, in the original packaging. Keep the capsules away from moisture, direct sunlight and excessive heat to maintain product stability and potency.

The capsules are intended for inhalation using a compatible dry‑powder inhaler device. The patient inhales the powdered medication deeply into the lungs or through the nasal route as directed by the prescriber, following the inhaler’s specific technique instructions.

Serious adverse events, although rare, include urinary retention, exacerbation of narrow‑angle glaucoma, paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, and angioedema. Patients should seek immediate medical attention if they experience symptoms such as difficulty urinating, eye pain, worsening breathing, swelling of the face or throat, or rash.

Ipratropium bromide is contraindicated in patients with a known hypersensitivity to ipratropium bromide or any of the capsule excipients. Caution is advised in individuals with severe urinary retention, uncontrolled narrow‑angle glaucoma, or those who have experienced paradoxical bronchospasm with anticholinergic therapy.